COO

MKT CAP:$13B

The Cooper Companies, Inc.

Market Cap

$13B

Healthcare·Medical - Instruments & Supplies·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$64.95-$16.16 (-19.92%)

Apr 23, 2026

Company Details

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, in...

CEO

Albert G. White

IPO Date

Jan 21, 1983

Website

www.coopercos.com

Key Metrics TTM

Revenue

$4.2B

+5.7% YoY

Net Income

$401M

EPS (Diluted)

$2.02

Free Cash Flow

$491M

Revenue / Share

$21.11

Gross Margin

64.2%

Operating Margin

17.2%

Net Margin

9.7%

FCF Margin

11.8%

P/S

3.0x

P/E

31.3x

Earnings Reports

Q1 2026

Mar 6, 2026

$1.0B+6.2%EPS $0.66

FY 2025

Dec 5, 2025

$4.1B+5.1%EPS $1.87

Q4 2025

Dec 5, 2025

$1.1B+4.6%EPS $0.43

Q3 2025

Aug 28, 2025

$1.1B+5.7%EPS $0.49

Q2 2025

May 30, 2025

$1.0B+6.3%EPS $0.44

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$830M	$533M	$133M
Q3 22	$843M	$552M	$141M
Q4 22	$848M	$537M	$104M
Q1 23	$859M	$559M	$150M
Q2 23	$877M	$583M	$96M
Q3 23	$930M	$610M	$152M
Q4 23	$927M	$607M	$136M
Q1 24	$932M	$624M	$153M
Q2 24	$943M	$631M	$162M
Q3 24	$1.0B	$663M	$193M
Q4 24	$1.0B	$678M	$198M
Q1 25	$965M	$660M	$182M
Q2 25	$1.0B	$679M	$185M
Q3 25	$1.1B	$692M	$176M
Q4 25	$1.1B	$601M	$140M
Q1 26	$1.0B	$695M	$213M

Valuation

Quarter	P/S	P/E
Q2 22	4.0x	13.3x
Q3 22	3.9x	29.2x
Q4 22	3.8x	32.6x
Q1 23	3.7x	33.5x
Q2 23	3.7x	43.6x
Q3 23	3.6x	45.6x
Q4 23	3.5x	42.7x
Q1 24	3.4x	43.2x
Q2 24	3.4x	37.0x
Q3 24	3.3x	35.0x
Q4 24	3.2x	32.0x
Q1 25	3.2x	30.3x
Q2 25	3.2x	30.3x
Q3 25	3.1x	30.8x
Q4 25	3.1x	33.5x
Q1 26	3.0x	31.3x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	$132M	$88M
Q3 22	$264M	$217M
Q4 22	$131M	$36M
Q1 23	$167M	$84M
Q2 23	$124M	$51M
Q3 23	$143M	$52M
Q4 23	$174M	$29M
Q1 24	$123M	$5M
Q2 24	$111M	$37M
Q3 24	$208M	$119M
Q4 24	$268M	$128M
Q1 25	$191M	$101M
Q2 25	$96M	$18M
Q3 25	$261M	$165M
Q4 25	$248M	$150M
Q1 26	$261M	$159M

Capital Expenditures

Quarter	CapEx
Q2 22	$43M
Q3 22	$47M
Q4 22	$95M
Q1 23	$83M
Q2 23	$74M
Q3 23	$91M
Q4 23	$145M
Q1 24	$118M
Q2 24	$74M
Q3 24	$89M
Q4 24	$140M
Q1 25	$89M
Q2 25	$78M
Q3 25	$97M
Q4 25	$98M
Q1 26	$102M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	+15.3%	+21.0%
Q3 22	+10.5%	+6.0%
Q4 22	+11.7%	+18.1%
Q1 23	+9.1%	+8.0%
Q2 23	+5.7%	+12.0%
Q3 23	+10.3%	+10.8%
Q4 23	+9.3%	+6.3%
Q1 24	+8.5%	+9.8%
Q2 24	+7.4%	-0.0%
Q3 24	+7.8%	+4.1%
Q4 24	+9.8%	+3.6%
Q1 25	+3.6%	+0.5%
Q2 25	+6.3%	+4.7%
Q3 25	+5.7%	+9.2%
Q4 25	+4.6%	+12.8%
Q1 26	+6.2%	+3.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$0	0.0%
Q3 22	$0	0.0%
Q4 22	$0	0.0%
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$0	0.0%
Q1 24	$0	0.0%
Q2 24	$0	0.0%
Q3 24	$0	0.0%
Q4 24	$0	0.0%
Q1 25	$0	0.0%
Q2 25	$0	0.0%
Q3 25	$0	0.0%
Q4 25	$0	0.0%
Q1 26	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q2 22	$26M	$322M	—
Q3 22	$29M	$343M	—
Q4 22	$29M	—	$358M
Q1 23	$32M	—	$331M
Q2 23	$33M	$408M	—
Q3 23	$37M	$375M	—
Q4 23	$37M	—	$388M
Q1 24	$40M	—	$381M
Q2 24	$39M	—	$380M
Q3 24	$39M	—	$381M
Q4 24	$38M	—	$391M
Q1 25	$41M	—	$388M
Q2 25	$46M	—	$399M
Q3 25	$45M	—	$422M
Q4 25	$41M	—	$419M
Q1 26	$44M	—	$390M

Revenue Segments

Quarter	Coopersurgical Segment	Coopervision Segment
Q2 22	$276M	$554M
Q3 22	$277M	$566M
Q4 22	$286M	$562M
Q1 23	$277M	$581M
Q2 23	$288M	$589M
Q3 23	$300M	$630M
Q4 23	$304M	$623M
Q1 24	$310M	$622M
Q2 24	$307M	$636M
Q3 24	$327M	$676M
Q4 24	$342M	$676M
Q1 25	$319M	$646M
Q2 25	$333M	$670M
Q3 25	$342M	$718M
Q4 25	$355M	$710M
Q1 26	$329M	$695M

Revenue by Geography

Quarter	Europe	Rest Of World, Excluding United States And Europe	United States
Q2 22	$243M	$168M	$419M
Q3 22	$256M	$169M	$418M
Q1 23	$248M	$176M	$435M
Q2 23	$250M	$185M	$443M
Q3 23	$280M	$188M	$463M
Q1 24	$277M	$185M	$470M
Q2 24	$277M	$187M	$479M
Q3 24	$297M	$195M	$511M
Q1 25	$288M	$181M	$496M
Q2 25	$292M	$195M	$515M
Q3 25	$343M	$201M	$516M
Q1 26	$326M	$184M	$514M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$399M	$0	$399M
Q3 22	$246M	$0	$246M
Q4 22	$138M	$0	$138M
Q1 23	$118M	$0	$118M
Q2 23	$112M	$0	$112M
Q3 23	$117M	$0	$117M
Q4 23	$121M	$0	$121M
Q1 24	$135M	$0	$135M
Q2 24	$112M	$0	$112M
Q3 24	$110M	$0	$110M
Q4 24	$108M	$0	$108M
Q1 25	$101M	$0	$101M
Q2 25	$116M	$0	$116M
Q3 25	$125M	$0	$125M
Q4 25	$111M	$0	$111M
Q1 26	$125M	$0	$125M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	199M	-0.4%	0.0%
Q3 22	198M	-0.2%	-0.4%
Q4 22	198M	0.0%	-0.6%
Q1 23	199M	+0.2%	-0.4%
Q2 23	199M	+0.2%	+0.2%
Q3 23	200M	+0.2%	+0.6%
Q4 23	200M	0.0%	+0.6%
Q1 24	200M	+0.2%	+0.6%
Q2 24	201M	+0.3%	+0.7%
Q3 24	201M	+0.0%	+0.5%
Q4 24	201M	+0.2%	+0.8%
Q1 25	201M	+0.0%	+0.7%
Q2 25	201M	-0.2%	+0.1%
Q3 25	201M	-0.0%	0.0%
Q4 25	198M	-1.2%	-1.5%
Q1 26	197M	-0.7%	-2.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$69.2K	12K
Q3 22	$70.3K	12K
Q4 22	$60.6K	14K
Q1 23	$61.3K	14K
Q2 23	$62.7K	14K
Q3 23	$66.4K	14K
Q4 23	$61.8K	15K
Q1 24	$62.1K	15K
Q2 24	$62.8K	15K
Q3 24	$66.9K	15K
Q4 24	$63.6K	16K
Q1 25	$60.3K	16K
Q2 25	$62.6K	16K
Q3 25	$66.3K	16K
Q4 25	$2M	500
Q1 26	$2M	500

Revenue / Employee